Computationally Designed Heparan Sulfates and Pathophysiology
Computationally Designed Heparan Sulfates and Pathophysiology
批准号:
8516576
负责人:
Umesh Ramanlal Desai
金额:
$31.59万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
AddressAffectAffinityAgonistAnimal ModelAnimal TestingAnticoagulantsAnticoagulationAreaAtomic Force MicroscopyBelief SystemBindingBiochemicalBiological ProcessBiologyBiopolymersChemistryClinicalCoagulation ProcessDevelopmentDiseaseEnzymesEscherichia coliFactor IXaFactor XaFibroblast Growth Factor 1Functional disorderGAG GeneGlycoproteinsGrowthGrowth FactorHIV Envelope Protein gp120HIV-1HeparinHeparin Cofactor IIHeparitin SulfateIL8 geneImmune responseIn VitroIndividualInflammationInstructionInvestigationKineticsKnowledgeLaboratoriesLegal patentLibrariesLow-Molecular-Weight HeparinModelingMolecularMorphologyNaturePaperPathologic ProcessesPeptide HydrolasesPharmacologic SubstancePhysiological ProcessesPlasmaPlayPositioning AttributePreparationPropertyProteinsResearchRoleSerpinsSimplexvirusSpecificityStructureStructure-Activity RelationshipSystemTechnologyTestingThermodynamicsThrombinThrombosisTimeViralVirtual LibraryWorkXenograft procedureangiogenesisbasebeta-Thromboglobulincapsular polysaccharide K5cell envelopechemokinecombinatorialcomputer studiesdesignevaluation/testingexperiencefondaparinuxheparin cofactorin vivoinhibitor/antagonistpathogenreceptorscreeningsulfotransferase
中文摘要
天然生物聚合物肝素和硫酸肝素在大量的生物活性物质中起着至关重要的作用
英文摘要
Natural biopolymers heparin and heparan sulfate play critical roles in a large number of biological
processes including coagulation, growth and morphology, angiogenesis, immune response, inflammation,
and pathogen invasion. In fact, heparin and its derivatives, low molecular weight heparins and fondaparinux,
are clinically used as anticoagulants in a number of thrombotic disorders. The fundamental basis for the use
of heparin in these disorders is its high affinity and high specificity interaction with antlthrombin, a plasma
glycoprotein and inhibitor of coagulation enzymes, especially thrombin, factor Xa and factor IXa. Despite the
longstanding use of heparin, it continues to suffer from a number of problems. Better heparin-based
anticoagulation therapy is critically needed, especially at a time when its heterogeneous nature can also give
rise to problems associated with contaminations. Additionally, although heparin and heparan sulfate play
important roles in other physiological and pathological processes, no clinical agent has as yet been devised.
The major reason for this state is the phenomenal structural diversity of H/HS, which results in a) the
difficulty of preparing HS preparations with defined structural composition and b) the difficulty of studying the
interaction of a large number of HS structures with multiple proteins. Major advances are necessary in these
two areas to decode H/HS structure - function relationships so as to enable the design of agonists and/or
antagonists for modulation of biological processes.
This Project 11 of the PEG addresses the fundamental difficulty of studying the interactions of all possible
HS sequences with any protein (i.e., area b) above) through a unique technology developed in the laboratory
of the PL called combinatorial virtual library screening (CVLS) technology. In combination with Projects I, III
and IV, we propose 1) to decipher fundamental aspects of HS structure - function relationships in the
coagulation and inflammation system, and 2) to test this enhanced understanding in in vivo animal models,
especially for the coagulation system. Thus, we propose to 1) study the importance of specific and non-
specific interactions of heparan sulfate with proteins using computational approaches and identify promising
structures for in vitro and in vivo investigation; 2) develop computationally designed HS structures as specific
activators of heparin cofactor II; and 3) investigate the interaction of designed H/HS with coagulation proteins
at a molecular level for development as new clinically useful anticoagulants.
RELEVANCE (See instructions):
Thrombotic disorders affect 1 in 3 individuals in the US. The proposed research involves the computational
design, biochemical evaluation and animal testing of heparan sulfates as modulators of thrombotic disorders.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Lead identification and pre-clinical studies on allosteric inhibitors of coagulation factor XIa
-
批准号:10722847
-
项目类别:
-
资助金额:$54.34万
-
财政年份:2022
-
负责人:Umesh Ramanlal Desai
-
依托单位:
Lead identification and pre-clinical studies on allosteric inhibitors of coagulation factor XIa
-
批准号:10369394
-
项目类别:
-
资助金额:$54.34万
-
财政年份:2022
-
负责人:Umesh Ramanlal Desai
-
依托单位:
Project 3: Role of Glycosaminoglycans in Hematopoiesis
-
批准号:10545019
-
项目类别:
-
资助金额:$58.96万
-
财政年份:2021
-
负责人:Umesh Ramanlal Desai
-
依托单位:
Project 3: Role of Glycosaminoglycans in Hematopoiesis
-
批准号:10088970
-
项目类别:
-
资助金额:$59.97万
-
财政年份:2021
-
负责人:Umesh Ramanlal Desai
-
依托单位:
Project 3: Role of Glycosaminoglycans in Hematopoiesis
-
批准号:10321582
-
项目类别:
-
资助金额:$53.07万
-
财政年份:2021
-
负责人:Umesh Ramanlal Desai
-
依托单位:
Tool for Predicting Glycosaminoglycan Recognition of Proteins
-
批准号:10062163
-
项目类别:
-
资助金额:$6.88万
-
财政年份:2019
-
负责人:Umesh Ramanlal Desai
-
依托单位:
Tool for Predicting Glycosaminoglycan Recognition of Proteins
-
批准号:10411438
-
项目类别:
-
资助金额:$6.88万
-
财政年份:2019
-
负责人:Umesh Ramanlal Desai
-
依托单位:
Tool for Predicting Glycosaminoglycan Recognition of Proteins
-
批准号:9813586
-
项目类别:
-
资助金额:$28.19万
-
财政年份:2019
-
负责人:Umesh Ramanlal Desai
-
依托单位:
Advanced Skills Development in Glyco-Hematology and Glyco-Oncology
-
批准号:9751362
-
项目类别:
-
资助金额:$12.26万
-
财政年份:2015
-
负责人:Umesh Ramanlal Desai
-
依托单位:
Advanced Skills Development in Glyco-Hematology and Glyco-Oncology
-
批准号:8949552
-
项目类别:
-
资助金额:$12.26万
-
财政年份:2015
-
负责人:Umesh Ramanlal Desai
-
依托单位:
Advanced Skills Development in Glyco-Hematology and Glyco-Oncology
-
批准号:9305126
-
项目类别:
-
资助金额:$12.26万
-
财政年份:2015
-
负责人:Umesh Ramanlal Desai
-
依托单位:
CHEMISTRY AND BIOLOGY OF HEPARAN SULFATE
-
批准号:8072341
-
项目类别:
-
资助金额:$240.4万
-
财政年份:2011
-
负责人:Umesh Ramanlal Desai
-
依托单位:
CHEMISTRY AND BIOLOGY OF HEPARAN SULFATE
-
批准号:9068299
-
项目类别:
-
资助金额:$229.54万
-
财政年份:2011
-
负责人:Umesh Ramanlal Desai
-
依托单位:
CHEMISTRY AND BIOLOGY OF HEPARAN SULFATE
-
批准号:8516573
-
项目类别:
-
资助金额:$210.25万
-
财政年份:2011
-
负责人:Umesh Ramanlal Desai
-
依托单位:
CHEMISTRY AND BIOLOGY OF HEPARAN SULFATE
-
批准号:8337397
-
项目类别:
-
资助金额:$229.82万
-
财政年份:2011
-
负责人:Umesh Ramanlal Desai
-
依托单位:
CHEMISTRY AND BIOLOGY OF HEPARAN SULFATE
-
批准号:8669104
-
项目类别:
-
资助金额:$217.45万
-
财政年份:2011
-
负责人:Umesh Ramanlal Desai
-
依托单位:
CHEMISTRY AND BIOLOGY OF HEPARAN SULFATE
-
批准号:9277558
-
项目类别:
-
资助金额:$229.73万
-
财政年份:2011
-
负责人:Umesh Ramanlal Desai
-
依托单位:
A Robust Predictive Method for Heparin and Heparan Sulfate Binding to Proteins
-
批准号:7933937
-
项目类别:
-
资助金额:$21.17万
-
财政年份:2009
-
负责人:Umesh Ramanlal Desai
-
依托单位:
Dual Direct Inhibitors of Thrombin and Factor Xa
-
批准号:7879296
-
项目类别:
-
资助金额:$37.38万
-
财政年份:2009
-
负责人:Umesh Ramanlal Desai
-
依托单位:
Dual Direct Inhibitors of Thrombin and Factor Xa
-
批准号:8267015
-
项目类别:
-
资助金额:$37.0万
-
财政年份:2009
-
负责人:Umesh Ramanlal Desai
-
依托单位:
海外基金